Skip to main content
    M

    MiMedx Group Inc (MDXG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.18
    -0.03 (-0.93%)

    Market Cap: $468.42M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    MiMedx Group Inc (MDXG) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect MiMedx Group (MDXG) to earn -$0.09 per share in the fiscal year ending Dec 31, 2026, on revenue of $256.63M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy120.0%
    Buy480.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 13.8%.

    Fiscal year ending Dec 31, 2026
    -$0.09
    EPS consensus, revenue $256.63M
    Fiscal year ending Dec 31, 2027
    $0.11
    EPS consensus, revenue $292.07M
    Next report
    Feb 23, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.09-$0.10 to -$0.083$256.63M$250.50M to $270.00M4
    Dec 31, 2027$0.11$0.04 to $0.173$292.07M$279.50M to $308.60M4

    Quarterly Estimates

    The EPS consensus rises from -$0.03 for the quarter ending Dec 31, 2026 to $0.01 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.03-$0.03 to -$0.037$67.86M$63.60M to $70.77M7
    Mar 31, 2027$0.01$0.01 to $0.012$65.47M$62.90M to $69.00M4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202700
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.05.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.09-$0.08-$0.06-$0.05-$0.05N/A
    Fiscal year ending Dec 31, 2027$0.11$0.11$0.11$0.11$0.17-38.4%
    Quarter ending Mar 31, 2027$0.01$0.03$0.04$0.04$0.04-75.0%

    Frequently Asked Questions About MDXG

    What is the MDXG stock forecast?

    Consensus analyst estimates put MiMedx Group's EPS at -$0.09 for the fiscal year ending Dec 31, 2026, on revenue of $256.63M. The consensus rating from 5 analysts is Buy.

    How do analysts rate MDXG stock?

    Of 5 analysts covering MiMedx Group, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from MDXG next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.09, with estimates from -$0.10 to -$0.08 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.11, with estimates from $0.04 to $0.17 from 3 analysts.

    What revenue do analysts expect from MiMedx Group next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $256.63M, with estimates from $250.50M to $270.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $292.07M, with estimates from $279.50M to $308.60M.

    How many analysts cover MDXG?

    5 analysts rate MiMedx Group stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.